The Male Infertility Market size was estimated at USD 4.78 billion in 2025 and expected to reach USD 5.07 billion in 2026, at a CAGR of 6.45% to reach USD 7.41 billion by 2032.

Male infertility is a clinically significant component of infertility, defined by the inability to achieve pregnancy after 12 months or more of regular unprotected intercourse. The condition is no longer viewed only as a reproductive endpoint; it is increasingly treated as a broader men’s health signal linked to sperm production, sperm motility, sperm morphology, varicocele, azoospermia, endocrine disorders, infection, genetic factors, metabolic health, environmental exposures, and lifestyle risks. Globally, infertility affects about 17.5% of adults-roughly one in six people-and the lifetime prevalence is similar in high-income countries and low- and middle-income countries, underscoring the need for equitable fertility care rather than assuming infertility is limited to affluent populations. Male factors alone account for an estimated 20–30% of infertility cases and contribute to about 50% of couple infertility, making male factor infertility, semen analysis, sperm DNA integrity, reproductive urology, IVF, ICSI, and assisted reproductive technology central keywords and central clinical priorities in the modern fertility care pathway.

The male infertility landscape is shifting from late-stage, couple-based investigation toward earlier, evidence-led evaluation of the male partner. Clinical guidance emphasizes that male infertility workup can prevent unnecessary, costly, time-consuming, and invasive treatment for the female partner, while also identifying treatable male factor conditions and medically important health risks. Standardization is another major shift: the sixth edition of the WHO semen analysis manual was designed to improve quality, comparability, and reproducibility across laboratories, which is essential for interpreting sperm concentration, motility, morphology, viability, and advanced andrology testing. At the same time, epidemiologic evidence has intensified focus on prevention and surveillance: a global GBD-based analysis estimated 56.5 million prevalent male infertility cases in 2019 and reported a 76.9% increase in prevalence since 1990, while a separate meta-regression of sperm count studies supported an appreciable decline in sperm concentration and total sperm count from 1973 to 2018 among unselected men. These shifts are reshaping care priorities toward earlier semen analysis, reproductive urology referral, lifestyle risk assessment, environmental exposure reduction, standardized lab quality, sperm DNA fragmentation evaluation where clinically appropriate, and integrated IVF/ICSI decision-making.

Artificial intelligence is becoming a cumulative layer across male infertility care rather than a single point solution. AI-enabled semen analysis can support more objective assessment of sperm motility, morphology, concentration, and image-based sperm classification, while machine learning models are being studied for sperm DNA fragmentation prediction, hormonal-pattern screening, sperm selection for ICSI, workflow triage, and patient communication. Reviews of AI in male infertility describe active research across semen analysis, assisted reproduction, hypogonadism, varicocele-related evaluation, and digital patient support, but they also stress the need for clinical validation, representative datasets, transparency, and outcome-based evidence before broad adoption. The strongest near-term value is likely to come from reducing inter-observer variability, improving laboratory quality control, supporting rare-sperm detection, and connecting semen parameters with clinical context; however, AI should not be positioned as a replacement for reproductive urologists, embryologists, or validated laboratory standards. A 2026 systematic review of AI in automated semen analysis concluded that randomized controlled trials are still needed to determine whether AI-guided sperm selection improves fertilization, implantation, pregnancy, or live-birth outcomes. Governance is equally important: AI used for medical purposes is increasingly evaluated under medical-device and software-as-a-medical-device frameworks, with U.S. regulators emphasizing lifecycle management and transparency for machine-learning medical devices and EU rules classifying AI-based medical software for medical purposes as high risk, requiring risk mitigation, high-quality datasets, clear user information, and human oversight.

Asia-Pacific presents the most complex male infertility profile because it combines large population exposure, rapid demographic change, variable access to reproductive urology, and high-volume assisted reproduction activity. East Asia had the highest regional number of male infertility cases in the GBD 2019 analysis, while South Asia and Southeast Asia also carried substantial years-lived-with-disability burdens; China and India ranked first and second globally by prevalent male infertility counts in that analysis. Europe is shaped by low fertility, strong registry infrastructure, and tightening quality standards; Eastern Europe recorded one of the highest age-standardized prevalence rates for male infertility, while the European Union’s new substances-of-human-origin framework extends protections to donors, recipients, and offspring born through medically assisted reproduction and will apply from August 7, 2027. North America is characterized by structured reporting, specialist referral pathways, and increasing emphasis on male partner evaluation; in the United States, male factor infertility represented 28.0% of reported reasons for ART cycles in 2022, reinforcing the clinical importance of semen analysis and reproductive urology integration. Latin America shows rising need for standardized access and data collection, with Central Latin America recording the highest percentage increase in age-standardized male infertility prevalence from 1990 to 2019, and the regional assisted reproduction registry identifying Brazil and Mexico as major contributors to reported ART activity. The Middle East faces a combined burden of cultural stigma, metabolic risk, and evolving fertility regulation; in the GBD analysis, North Africa and the Middle East showed a large increase in male infertility prevalence from 1990 to 2019. Africa requires the most urgent equity lens because Western Sub-Saharan Africa recorded the highest age-standardized prevalence and YLD rates for male infertility, with Cameroon, Guinea, Senegal, Liberia, and Mauritania among the countries with the highest age-standardized male infertility prevalence rates in 2019.

Across NATO-aligned health systems, male infertility priorities are concentrated in data integrity, reproductive medicine resilience, cybersecurity for fertility laboratories, and harmonized standards because many member countries overlap with North American and European systems that already rely on national or regional ART registries and specialist guidance. For the G7, the strategic issue is demographic pressure combined with high clinical expectations: the United States, Canada, France, Germany, Italy, Japan, and the United Kingdom all report fertility rates below the replacement level, while male factors contribute to about half of couple infertility, making male partner evaluation an essential component of fertility policy and care efficiency. The European Union is moving toward stronger cross-border quality oversight through the SoHO Regulation, which explicitly includes reproductive substances such as sperm, oocytes, and embryos and expands protections for offspring from medically assisted reproduction. BRICS economies carry a scale-driven burden because China and India ranked highest in male infertility prevalence counts in the GBD 2019 analysis, while Brazil and Russia add large, demographically pressured populations with sub-replacement fertility, reinforcing the need for accessible semen analysis, varicocele care, endocrine evaluation, and ICSI-ready andrology capacity. ASEAN countries sit at the intersection of youthful population structures in some members and rapidly declining fertility in others; Southeast Asia’s substantial male infertility YLD burden indicates that affordable diagnostics, infection control, and standardized laboratory protocols should be prioritized alongside assisted reproduction capacity. The GCC should be viewed through a Middle East-specific lens in which highly specialized fertility services coexist with variable disclosure, stigma, and metabolic risk factors; World Bank data show several Gulf economies already below replacement fertility, while global clinical sources identify obesity, smoking, heavy alcohol use, anabolic steroid use, diabetes, infections, environmental toxins, and heat exposure as relevant male infertility risk factors.

The United States has one of the strongest ART reporting infrastructures, and CDC data show male factor infertility accounted for 28.0% of ART cycle reasons in 2022, supporting continued integration of reproductive urology into fertility pathways. China and India require scale-sensitive approaches because they ranked first and second globally in prevalent male infertility counts in the GBD 2019 analysis, while both countries also face major demographic transition pressures; China’s 2023 total fertility rate was listed at 1.0 births per woman and India’s at 2.0 in World Bank data. Germany, France, Spain, Italy, and the United Kingdom operate within mature European fertility systems, but their 2023 total fertility rates-1.4 in Germany, 1.7 in France, 1.1 in Spain, 1.2 in Italy, and 1.6 in the United Kingdom-show why male infertility evaluation, semen analysis quality, donor sperm governance, and ICSI decision protocols remain policy-relevant across Europe. Japan and South Korea are among the most demographically pressured advanced economies, with 2023 fertility rates of 1.2 and 0.7 respectively; for these countries, male infertility care should be linked with delayed parenthood, sperm preservation, genetic testing for severe male factor infertility, and efficient ART triage. Australia and Canada combine high-income care infrastructure with sub-replacement fertility, recorded at 1.5 and 1.3 births per woman in 2023, making standardized andrology, reproductive endocrinology collaboration, and transparent patient counseling important care differentiators. Russia, Brazil, and Mexico are critical bridge markets for male infertility care delivery: Russia and Brazil show sub-replacement fertility in World Bank data, Mexico was listed at 1.9 births per woman in 2023, and Latin American registry evidence shows Brazil and Mexico as leading contributors to regional ART activity, reinforcing the need for broader access to semen analysis, sperm DNA testing where indicated, microsurgical expertise, and affordable assisted reproduction pathways.

Industry leaders should make male factor infertility visible at the first point of fertility care by embedding early semen analysis, repeat testing where appropriate, reproductive urology referral criteria, endocrine evaluation, varicocele assessment, and genetic workup for severe oligozoospermia or azoospermia into standard pathways. Laboratories should align semen analysis with WHO sixth-edition methods, invest in external quality assurance, and clearly communicate the limits of sperm concentration, motility, morphology, and sperm DNA fragmentation testing. AI adoption should follow a validation-first strategy: leaders should require dataset diversity, clinical performance evidence, human oversight, audit trails, bias monitoring, cybersecurity controls, and lifecycle management before deploying AI semen analysis or AI sperm selection. Care models should also address modifiable risks-obesity, smoking, anabolic steroid use, heavy alcohol use, heat exposure, diabetes, infections, radiation, medications, and environmental toxins-because prevention and male health optimization can improve counseling and may identify non-reproductive disease risks. Finally, leaders should build inclusive access strategies by reducing stigma around male infertility, educating primary care and urology networks, strengthening sperm preservation services for oncology and high-risk treatments, and publishing transparent outcomes without overstating success.

This executive summary was developed through structured secondary research using verified public-health, clinical, regulatory, demographic, and peer-reviewed sources. Core epidemiologic inputs were drawn from WHO infertility publications, GBD-based male infertility analyses, sperm count meta-regression research, World Bank demographic indicators, and national or regional ART registries. Clinical and laboratory interpretation was grounded in AUA/ASRM guidance, WHO semen laboratory standards, CDC infertility risk-factor information, and peer-reviewed reviews of AI in semen analysis and sperm selection. Regulatory context was validated through official U.S. and European public sources covering AI-enabled medical-device oversight and the EU substances-of-human-origin framework. Commercial estimates, revenue calculations, market sizing, market share statements, and market forecasts were intentionally excluded to maintain a strictly evidence-backed clinical and policy orientation.

Male infertility is a high-impact reproductive health issue that intersects with men’s health, demographic resilience, laboratory medicine, AI-enabled diagnostics, environmental health, and equitable access to fertility care. The evidence shows a meaningful global burden, strong regional variation, rising attention to sperm quality, and persistent under-evaluation of the male partner despite the fact that male factors contribute to about half of couple infertility. The next phase of progress will depend on standardized semen analysis, earlier reproductive urology involvement, validated AI tools, transparent ART reporting, stronger donor and laboratory governance, and care models that treat male infertility as both a fertility challenge and a broader health signal. Organizations that prioritize clinical validity, access, quality, and patient-centered communication will be best positioned to improve outcomes in male factor infertility while avoiding unsupported claims.